Digital Biomarkers Market

The digital biomarkers market is expected to reach USD 15.60 billion by 2030 from USD 6.30 billion in 2025, at a CAGR of 19.9% between 2025 and 2030. The growth of the digital biomarkers market is driven by several key factors, including the expansion of wearables & remote monitoring devices and the integration of advanced analytics & AI.

Several key players in the digital biomarkers industry include Ametris (US), AliveCor (US), BioSensics (US), Mindstrong Health (US), iCOMETRIX (Belgium), BACtrack (US), AccuLabs (US), and AtCor Medical (Australia), among others. Companies in this space are adopting expansion strategies to strengthen their global footprint and advance their technology portfolios. In February 2023, Ametris and uMotif partnered to provide patient-centered solutions for clinical research, combining ActiGraph’s wearable technology with uMotif’s patient engagement platform.

To know about the assumptions considered for the study download the pdf brochure

Ametris (US)

Ametris is a major player in the digital biomarkers industry and focuses on developing and validating data-driven biomarkers based on multimodal digital health data, including physiological signals, behavioral data, and real-world patient data. The company’s platforms are designed to convert continuous, high-frequency data streams into meaningful digital endpoints for early disease detection, disease progression, and therapeutic response. By concentrating on scalable analytics, interoperability with digital health ecosystems, and applicability across clinical research and real-world environments, Ametris helps healthcare and life sciences stakeholders to incorporate digital biomarkers into decentralized care models and data-enabled clinical workflows.

AliveCor (US)

AliveCor is a prominent player in the digital biomarkers market through its AI-powered ECG technology that converts wearable and mobile cardiac data into clinically validated digital biomarkers. Its Kardia platform enables real-time and longitudinal assessment of cardiac rhythm abnormalities, supporting the identification and monitoring of conditions such as atrial fibrillation and other arrhythmias. The integration of regulatory-cleared algorithms, cloud-based analytics, and EHR-compatible reporting supports adoption across clinical practices and remote care environments, positioning AliveCor as a key enabler of decentralized cardiovascular monitoring and digital-first cardiac diagnostics.

BioScensis (US)

BioScensis participates in the digital biomarkers market by leveraging advanced signal processing, machine learning, and biosensor-derived data to generate validated digital biomarkers for clinical and research applications. The company focuses on transforming complex biological and physiological datasets into actionable insights for disease monitoring, patient stratification, and outcome measurement. Through flexible software platforms and compatibility with existing digital health and clinical research infrastructures, BioScensis supports the incorporation of digital biomarkers into routine care, remote patient monitoring, and decentralized clinical trials.

Market Ranking

The digital biomarkers market is increasingly shaped by a mix of platform-centric digital health companies and analytics-driven specialists that are defining standards for real-world data capture, validation, and clinical adoption. Ametris (US) focuses on transforming multimodal digital health data into clinically relevant digital biomarkers to support disease monitoring and therapeutic response assessment across decentralized care and research settings. AliveCor (US) has established a strong position through its AI-enabled ECG platforms, converting wearable cardiac data into FDA-cleared digital biomarkers for arrhythmia detection and longitudinal cardiovascular monitoring in both clinical and remote care environments. BioScensis contributes to the market by applying advanced signal processing and machine learning to biosensor-derived data, enabling the generation of validated digital endpoints for clinical research and real-world evidence applications. Mindstrong (US) specializes in smartphone-based behavioral and cognitive biomarkers, leveraging both passive and active digital signals to support the assessment of neurological and psychiatric conditions in decentralized, real-world settings. iCometrix (Belgium) strengthens the neuro-focused segment of the market through its AI-driven imaging analytics platforms, which convert MRI data into quantitative digital biomarkers for neurological disease diagnosis, progression tracking, and treatment monitoring, thereby supporting adoption across hospitals, research networks, and precision neurology programs.

Related Reports:

Digital Biomarkers Market by Product (Wearables, Sensors, Mobile-based Applications), Type (Physiological, Idiosyncratic), Disease Indication (Autoimmune, Cardiovascular), End User (Pharma & Biotech Companies, Medtech Companies) – Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com